MAPS Trademark

Trademark Overview

On Friday, October 18, 2019, a trademark application was filed for MAPS with the United States Patent and Trademark Office. The USPTO has given the MAPS trademark a serial number of 88659855. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, April 8, 2024. This trademark is owned by Affinivax, Inc.. The MAPS trademark is filed in the Pharmaceutical Products category with the following description:

vaccines; vaccines for the prophylaxis and treatment of infectious diseases and cancer; vaccines, namely, immunotherapies for the treatment of infectious diseases and cancer; vaccines comprising polysaccharide antigens and protein-based antigens; vaccines, namely, immunotherapies comprising polysaccharide antigens and protein-based antigens
maps

General Information

Serial Number88659855
Word MarkMAPS
Filing DateFriday, October 18, 2019
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, April 8, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 5, 2021

Trademark Statements

Goods and Servicesvaccines; vaccines for the prophylaxis and treatment of infectious diseases and cancer; vaccines, namely, immunotherapies for the treatment of infectious diseases and cancer; vaccines comprising polysaccharide antigens and protein-based antigens; vaccines, namely, immunotherapies comprising polysaccharide antigens and protein-based antigens

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, October 22, 2019
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameAffinivax, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWilmington, DE 19808
Party NameAffinivax, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressLexington, MA 02420

Trademark Events

Event DateEvent Description
Monday, April 8, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, April 8, 2024ABANDONMENT - NO USE STATEMENT FILED
Wednesday, October 4, 2023CORRECTED NOA E-MAILED
Tuesday, October 3, 2023DIVISIONAL PROCESSING COMPLETE
Friday, September 22, 2023DIVISIONAL REQUEST RECEIVED
Friday, September 22, 2023TEAS REQUEST TO DIVIDE RECEIVED
Tuesday, September 12, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 11, 2023SOU EXTENSION 5 GRANTED
Thursday, August 31, 2023SOU EXTENSION 5 FILED
Monday, September 11, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Thursday, August 31, 2023SOU TEAS EXTENSION RECEIVED
Friday, February 24, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 22, 2023SOU EXTENSION 4 GRANTED
Wednesday, February 22, 2023SOU EXTENSION 4 FILED
Wednesday, February 22, 2023SOU TEAS EXTENSION RECEIVED
Wednesday, October 26, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, October 26, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, October 26, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, October 21, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Friday, October 21, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, October 21, 2022TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Friday, October 21, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, October 21, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, October 21, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Saturday, July 30, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, July 28, 2022SOU EXTENSION 3 GRANTED
Thursday, July 28, 2022SOU EXTENSION 3 FILED
Thursday, July 28, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, January 12, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, January 10, 2022SOU EXTENSION 2 GRANTED
Monday, January 10, 2022SOU EXTENSION 2 FILED
Monday, January 10, 2022SOU TEAS EXTENSION RECEIVED
Wednesday, August 25, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 23, 2021SOU EXTENSION 1 GRANTED
Monday, August 23, 2021SOU EXTENSION 1 FILED
Monday, August 23, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, March 2, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 5, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 5, 2021PUBLISHED FOR OPPOSITION
Wednesday, December 16, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, November 30, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, May 28, 2020NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Thursday, May 28, 2020LETTER OF SUSPENSION E-MAILED
Thursday, May 28, 2020SUSPENSION LETTER WRITTEN
Tuesday, May 12, 2020TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, May 12, 2020CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, May 6, 2020TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, April 9, 2020ASSIGNED TO LIE
Thursday, April 2, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, April 2, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, April 2, 2020TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Thursday, April 2, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, April 2, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Thursday, April 2, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, November 7, 2019NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, November 7, 2019NON-FINAL ACTION E-MAILED
Thursday, November 7, 2019NON-FINAL ACTION WRITTEN
Thursday, November 7, 2019ASSIGNED TO EXAMINER
Tuesday, October 22, 2019NEW APPLICATION OFFICE SUPPLIED DATA ENTERED

Related Keywords

maps vaccines antigens based comprising polysaccharide immunotherapies protein namely treatment cancer